array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Regeneron Pharmaceuticals Inc" ["slug"]=> string(38) "c469a-us-regeneron-pharmaceuticals-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77" ["description"]=> string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. " ["address_street"]=> string(25) "777 Old Saw Mill River Rd" ["address_place"]=> string(9) "Tarrytown" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1988-02-08" ["website_domain"]=> string(13) "regeneron.com" ["website_url"]=> string(25) "https://www.regeneron.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(10368) ["article_count"]=> int(2748) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(173) "Trending Report on Age-related Vision Dysfunction Market 2024-2031 Business Outlook, Critical Insight and Growth Strategy | Novartis, Regeneron Pharmaceuticals, Roche, Bayer" ["snippet_en"]=> string(228) "Press release - CoherentMI - Trending Report on Age-related Vision Dysfunction Market 2024-2031 Business Outlook, Critical Insight and Growth Strategy | Novartis, Regeneron Pharmaceuticals, Roche, Bayer - published on openPR.com" ["url"]=> string(92) "https://www.openpr.com/news/3719127/trending-report-on-age-related-vision-dysfunction-market" ["image_url"]=> string(78) "https://images.businessradar.com/articles/05dde8b3-e46a-4ba0-9fcb-765af34695ca" ["source"]=> string(10) "openpr.com" ["publication_date"]=> string(10) "2024-11-05" ["categories"]=> array(1) { [0]=> string(14) "Product Launch" } } [1]=> array(7) { ["title_en"]=> string(53) "Amgen Launches Its Aflibercept Biosimilar In the U.S." ["snippet_en"]=> string(281) "After the Federal Circuit’s denial last month of Regeneron’s motion for an injunction pending appeal, seeking to prevent Amgen from launching its aflibercept biosimilar, Amgen announced on its Q3 earnings call last week that it has launched its aflibercept biosimilar, PAVBLU." ["url"]=> string(97) "https://www.bigmoleculewatch.com/2024/11/04/amgen-launches-its-aflibercept-biosimilar-in-the-u-s/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/f5eafc47-8794-4445-9c3e-b34794094d71" ["source"]=> string(20) "bigmoleculewatch.com" ["publication_date"]=> string(10) "2024-11-04" ["categories"]=> array(4) { [0]=> string(10) "New Market" [1]=> string(14) "Product Launch" [2]=> string(5) "Legal" [3]=> string(24) "Quarterly/Annual Figures" } } [2]=> array(7) { ["title_en"]=> string(51) "Amgen to launch Eylea biosimilar after court ruling" ["snippet_en"]=> string(260) "Amgen will launch Pavblu, its biosimilar to Regeneron's Eylea, after a US Court of Appeals decision denied Regeneron's request to halt the launch. The ruling allows Amgen to expand access to its treatment despite Regeneron's ongoing patent infringement claims." ["url"]=> string(84) "https://www.aiche.org/news/industry/amgen-launch-eylea-biosimilar-after-court-ruling" ["image_url"]=> NULL ["source"]=> string(9) "aiche.org" ["publication_date"]=> string(10) "2024-11-04" ["categories"]=> array(5) { [0]=> string(5) "Legal" [1]=> string(10) "Litigation" [2]=> string(18) "Expansion & Growth" [3]=> string(8) "Verdicts" [4]=> string(14) "Product Launch" } } [3]=> array(7) { ["title_en"]=> string(114) "Evercore sees Regeneron share price decline as overreaction, bullish on Dupixent as growth engine By Investing.com" ["snippet_en"]=> string(288) "Evercore ISI revised its outlook on Regeneron Pharmaceuticals (NASDAQ: REGN ) on Thursday, lowering its target price on the stock to $1,175.00 from $1,250.00, but maintaining an "Outperform" rating. This adjustment is in response to the expectation that rival drugs may be launched early." ["url"]=> string(63) "https://cn.investing.com/news/company-news/article-93CH-2528069" ["image_url"]=> NULL ["source"]=> string(13) "investing.com" ["publication_date"]=> string(10) "2024-10-26" ["categories"]=> array(4) { [0]=> string(18) "General Investment" [1]=> string(14) "Product Launch" [2]=> string(12) "Stock Market" [3]=> string(15) "Market Movement" } } [4]=> array(7) { ["title_en"]=> string(107) "Amgen Plans At-Risk Launch of EYLEA® Biosimilar Pavblu™ After Federal Circuit Lifts Temporary Injunction" ["snippet_en"]=> string(151) "On October 22, 2024, the Federal Circuit (CAFC Case No. 24-2351) denied Regeneron’s request for an injunction pending appeal for Amgen’s EYLEA®..." ["url"]=> string(80) "https://www.jdsupra.com/legalnews/amgen-plans-at-risk-launch-of-eylea-r-2420962/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/463e3318-d267-4e13-ad2d-00d3bba8336f" ["source"]=> string(11) "jdsupra.com" ["publication_date"]=> string(10) "2024-10-24" ["categories"]=> array(2) { [0]=> string(14) "Product Launch" [1]=> string(5) "Legal" } } [5]=> array(7) { ["title_en"]=> string(59) "Legal win leads Amgen to at-risk launch of Eylea biosimilar" ["snippet_en"]=> string(100) "Appeals court lifts injunction on the launch of Amgen's biosimilar of Regeneron's blockbuster Eylea." ["url"]=> string(80) "https://pharmaphorum.com/news/legal-win-leads-amgen-risk-launch-eylea-biosimilar" ["image_url"]=> string(78) "https://images.businessradar.com/articles/ca1e2efe-49c4-42d7-b814-5176f97a44d7" ["source"]=> string(16) "pharmaphorum.com" ["publication_date"]=> string(10) "2024-10-24" ["categories"]=> array(2) { [0]=> string(14) "Product Launch" [1]=> string(5) "Legal" } } [6]=> array(7) { ["title_en"]=> string(59) "Regeneron: a new protagonist in the Italian oncology sector" ["snippet_en"]=> string(294) "Regeneron is a biotech company that recently appeared on the Italian scene, but a world leader in biotechnology. Founded in 1988 by two scientists, it is dedicated to the development of innovative drugs and monoclonal antibodies for which it has developed a cutting-edge platform exploiting the" ["url"]=> string(118) "https://www.pharmastar.it/pharmastartv//business/regeneron-un-nuovo-protagonista-nel-settore-oncologico-italiano-13311" ["image_url"]=> string(78) "https://images.businessradar.com/articles/22d4323b-afd5-41bd-84c9-fd568cfeea79" ["source"]=> string(13) "pharmastar.it" ["publication_date"]=> string(10) "2024-10-23" ["categories"]=> array(3) { [0]=> string(14) "Product Launch" [1]=> string(5) "R & D" [2]=> string(5) "Fraud" } } [7]=> array(7) { ["title_en"]=> string(234) "Proprotein Convertase Subtilisin Kexin Type 9 Market Growth Trends Regional Analysis Segmentation Application Restraints Key Players Profile Forecast To By 2024-2031 | AFFiRiS AG, Sanofi and Regeneron Pharmaceuticals Inc, Novartis AG." ["snippet_en"]=> string(288) "Press release - DataM Intelligence 4Market Research - Proprotein Convertase Subtilisin Kexin Type 9 Market Growth Trends Regional Analysis Segmentation Application Restraints Key Players Profile Forecast To By 2024-2031 | AFFiRiS AG, Sanofi and Regeneron Pharmaceuticals Inc, Novartis AG." ["url"]=> string(95) "https://www.openpr.com/news/3704511/proprotein-convertase-subtilisin-kexin-type-9-market-growth" ["image_url"]=> string(78) "https://images.businessradar.com/articles/11fd18bc-bac2-48be-b414-3726fa784912" ["source"]=> string(10) "openpr.com" ["publication_date"]=> string(10) "2024-10-23" ["categories"]=> array(2) { [0]=> string(14) "Product Launch" [1]=> string(11) "Competition" } } [8]=> array(7) { ["title_en"]=> string(66) "Regeneron loses bid to block Amgen's Eylea biosimilar launch in US" ["snippet_en"]=> string(178) "Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said." ["url"]=> string(139) "https://www.reuters.com/business/healthcare-pharmaceuticals/amgen-launch-us-eylea-biosimilar-after-ruling-regeneron-patent-case-2024-10-22/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/7e51f5f7-6c09-44a2-a8eb-8c20ed0d1ed8" ["source"]=> string(11) "reuters.com" ["publication_date"]=> string(10) "2024-10-22" ["categories"]=> array(3) { [0]=> string(14) "Product Launch" [1]=> string(5) "Legal" [2]=> string(8) "Verdicts" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(263) } [1]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(201) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(196) } [3]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(129) } [4]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(116) } [5]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(116) } [6]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(93) } [7]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(79) } [8]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(67) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(66) } [10]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(61) } [11]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(59) } [12]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(57) } [13]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(56) } [14]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(53) } [15]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(43) } [16]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(40) } [17]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(38) } [18]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(37) } [19]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(37) } [20]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(37) } [21]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(35) } [22]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(33) } [23]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(32) } [24]=> array(2) { ["name"]=> string(13) "Data Security" ["count"]=> int(31) } [25]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(28) } [26]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(28) } [27]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(25) } [28]=> array(2) { ["name"]=> string(11) "Sponsorship" ["count"]=> int(21) } [29]=> array(2) { ["name"]=> string(21) "Intellectual Property" ["count"]=> int(20) } } } c469a-us-regeneron-pharmaceuticals-inc